REGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Regeneron Pharmaceuticals Inc. (REGN) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock is supported by strong hedge fund buying, positive news catalysts, and a robust pipeline. Despite minor financial setbacks in Q4 2025, the company's growth potential remains significant, particularly with its recent FDA approval for Otarmeni and ongoing Dupixent dominance.
The MACD is positive and expanding, suggesting bullish momentum. RSI is neutral at 66.459, indicating no overbought or oversold conditions. The stock is trading near its resistance level (R1: 766.495), which could signal a breakout if surpassed. Moving averages are converging, showing consolidation.
FDA approval for Otarmeni, the first gene therapy to restore neurosensory function, with potential for further clinical trial success.
Hedge funds increasing their positions by 167% last quarter.
Strong pipeline with undervalued assets like Lynozyfic and Dupixent expansion.
Positive sentiment from analysts with multiple Buy and Overweight ratings.
Financial performance in Q4 2025 showed a decline in net income (-7.97%) and EPS (-2.97%).
Potential headwinds from biosimilar competition for Eylea.
Seasonal and macroeconomic challenges noted by analysts.
In Q4 2025, revenue increased by 2.51% YoY to $3.88B, while net income and EPS declined by 7.97% and 2.97%, respectively. Gross margin improved slightly to 89.4%. The company shows resilience in revenue growth but faces challenges in profitability.
Analysts are generally positive on REGN, with multiple Buy and Overweight ratings. Price targets range from $765 to $975, with the most recent target raised to $960 by TD Cowen. Analysts highlight Dupixent's dominance, pipeline opportunities, and undervalued growth potential.
